Announcements Trials
Browse Landscape

Phase

Phase 2 9Phase 1 4Phase 1/2 3

Status

Terminated 2Withdrawn 1

Sponsor Class

OTHER 3INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Lymphoid 3

Conditions

Lymphoma, Non-Hodgkin 1Lymphoma, Mantle-Cell 1Lymphoma, Follicular 1Hodgkin Disease 1

Interventions

Cyclophosphamide 250Radiotherapy 172pembrolizumab 154Carboplatin 146Gemcitabine 139Nivolumab 135Paclitaxel 129Dexamethasone 118Cisplatin 118fludarabine 115Rituximab 104Lenalidomide 103Bevacizumab 99Docetaxel 97Capecitabine 97fludarabine phosphate 92Temozolomide 89Cytarabine 89Oxaliplatin 87Etoposide 82Filgrastim 77Irinotecan 73Doxorubicin 73venetoclax 70Peripheral Blood Stem Cell Transplantation 68Fluorouracil 68Radiosurgery 66Melphalan 66Everolimus 66Bortezomib 66

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1/2 × OTHER × umbralisib × Clear all
NCT04692155 2023-09-28

CHOP U2

University of Alabama at Birmingham

Phase 1/2 Terminated
1 enrolled 5 charts
Lymphoid

Lymphoma, Mantle-Cell

NCT05152459 2023-05-31

Tazemetostat in Combination With Umbralisib and Ublituximab for the Treatment Relapsed or Refractory Follicular Lymphoma

City of Hope Medical Center

Phase 1/2 Withdrawn
Lymphoid

Lymphoma, Follicular

NCT02867618 2021-07-16

Carfilzomib and TGR-1202 in Treatment of R/R Lymphoma

Columbia University

Phase 1/2 Terminated
14 enrolled 9 charts
Lymphoid

Hodgkin Disease, Lymphoma, Non-Hodgkin

Data powered by HemOnc (CC BY 4.0) Colophon âš¡